Salarius Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity (D
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
| Common Stock (1) · Additional Paid-In Capital · Accumulated Deficit · Total Stockholders' Equity (Deficit) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2023 | 492,304 | $49 | $81,635,074 | $(76,347,841) | $5,287,282 | |||
| Issuance of equity securities, net | 47,000 | 5 | 33 | — | 38 | |||
| Equity-based compensation expense | — | — | 77,508 | — | 77,508 | |||
| Net loss | — | — | — | (1,715,290) | (1,715,290) | |||
| Balance at March 31, 2024 | 539,304 | $54 | $81,712,615 | $(78,063,131) | $3,649,538 | |||
| Issuance of equity securities and other, net | 101,873 | 10 | 65,070 | — | 65,080 | |||
| Equity-based compensation expense | — | — | 85,168 | — | 85,168 | |||
| Net loss | — | — | — | (1,424,433) | (1,424,433) | |||
| Balance at June 30, 2024 | 641,177 | $64 | $81,862,853 | $(79,487,564) | $2,375,353 | |||
| Balance at December 31, 2024 | 1,441,157 | $144 | $83,435,169 | $(81,923,618) | $1,511,695 | |||
| Issuance of equity securities, net | 640,682 | 64 | 226,106 | — | 226,170 | |||
| Equity-based compensation expense | — | — | 33,534 | — | 33,534 | |||
| Net loss | — | — | — | (1,709,533) | (1,709,533) | |||
| Balance at March 31, 2025 | 2,081,839 | $208 | $83,694,809 | $(83,633,151) | $61,866 | |||
| Issuance of equity securities, net | 45,447 | 5 | 43,075 | — | 43,080 | |||
| Equity-based compensation expense | — | — | 23,155 | — | 23,155 | |||
| Net loss | — | — | — | (957,825) | (957,825) | |||
| Balance at June 30, 2025 | 2,127,286 | $213 | $83,761,039 | $(84,590,976) | $(829,724) | |||
(1)Share and per share amounts have been restated to reflect the 1-for-8 reverse stock split effected in June 14, 2024 on retroactive basis for all periods presented.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.